Grand Rapids device manufacturer prepares for $105 million IPO amid increase in implant sales

A medical device manufacturer in West Michigan is planning to launch an initial public offering (IPO) to raise approximately $105 million in capital. What began is a development to support their expansion plans and invest in research and development emerged from the innovative work of Shoulder Innovations Inc., a Grand Rapids-based company. The company is based on the southwest side of Grand Rapids and is aiming to issue 5 million shares of common stock, estimated at a price range of $19 to $21 per share. The shares will be listed for trading on the New York Stock Exchange under the symbol SI.Having recently filed with the U.S. Securities and Exchange Commission, Shoulder Innovations stated that about $75 million from the IPO proceeds will be allocated to strengthening their commercial operations. This includes hiring additional sales staff and expanding the commercial leadership team. The company also plans to invest in more instrument sets to accommodate expected growth in volume and geographical expansion. With a vision for the future, Shoulder Innovations highlighted their pipeline of new technologies that are currently under development and evaluation.In addition to the $75 million for commercial expansion, Shoulder Innovations earmarked $10 million for ongoing research and development initiatives around implant systems. The remaining funds from the IPO will be directed towards working capital and other general corporate purposes. Shoulder Innovations’ CEO Rob Ball refrained from providing comments to the media on the planned IPO. The company has been backed by the Grand Rapids-based Genesis Innovation Group, which is a crucial supporter of their technological advancements.Shoulder Innovations has carved a niche for itself with its InSet implant system, designed for individuals suffering from shoulder injuries and degenerative diseases. This innovative system simplifies surgical procedures, leading to better outcomes with reduced complications and improved implant longevity. In its IPO filing, Shoulder Innovations estimated the U.S. market potential for arthroplasty procedures to be around $1.7 billion. They anticipate a growth trajectory of 11% annually through 2029 with an estimated 250,000 arthroplasty procedures to be performed in the U.S. in 2025 alone.Most notably, Shoulder Innovations’ sales volumes have seen substantial growth over the past two years. The number of shoulder implant systems sold in the U.S. nearly tripled from 559 in the first quarter of 2023 to 1,503 in the first quarter of 2025. During this period, the company distributed close to 10,000 implant systems to various healthcare facilities in the U.S. through a network of independent distributors.The company foresees significant opportunities not only in the U.S. but also globally within the shoulder surgical care market. They are looking to expand internationally, starting with strategic market entries in select countries. As they continue to grow, the company envisions diversifying their product line to address various aspects of shoulder surgical care. This expansion strategy is aimed at capturing emerging opportunities and enhancing their product offerings in alignment with market demand.Morgan Stanley, Goldman Sachs Group Inc., and Piper Sandler Cos have been appointed to lead Shoulder Innovations’ IPO, steering the company through this crucial phase of fundraising. With reported revenues of $31.6 million in 2024, a marked increase of 64% from the previous year, Shoulder Innovations is on a growth trajectory. The revenue for the first quarter of 2025 stood at $10.1 million, compared to $7.2 million in 2023. Moreover, the company recently secured a $40 million investment from Fidelity Management & Research Co. in convertible notes, aligning their financial position in preparation for the IPO.Shoulder Innovations has embarked on an exciting journey filled with promise, innovation, and growth. Through strategic investments in product development, team expansion, and global reach, the company is poised to make a significant impact in the healthcare industry and revolutionize shoulder surgical care.